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Abstract
Background: Comparing survival of patients with a single tumour and patients with multiple
primaries poses different methodological problems. In population based studies, where we cannot
rely on detailed clinical information, the issue is disentangling the share of survival probability from
the first and second cancer, and their compounded effect. We examined three hypotheses: A) the
survival probability since the first tumour does not change with the occurrence of a second tumour;
B) the probability of surviving a tumour does not change with the presence of a previous primary;
C) the probabilities of surviving two subsequent primary tumours are independent (additivity
hypothesis on mortality rates).
Methods: We studied the survival probabilities modelling mortality rates according to hypotheses
A), B) and C). Mortality rates were calculated using Aalen-Johansen estimators which allowed to
discount for the lag-time survival before developing a second tumour. We applied this approach to
a cohort of 436 women with breast cancer (BC) and a subsequent tumour in the resident
population of Turin, Italy, between 1985 and 2002.
Results: We presented our results in term of a Standardised Mortality Ratio calculated (SMRAJ)
after 10 years of follow-up. For hypothesis A we observed a significant excess mortality of 2.21
(95% C.I. 1.94 – 2.45). Concerning hypothesis B we found a not significant SMRAJ of 0.98 (95% C.I.
0.87 – 1.10). The additivity hypothesis (C) was not confirmed as it overestimated the risk of death,
in fact SMRsAJ were all below 1: 0.75 (95% C.I. 0.66 – 0.84) for BC and all subsequent cancers, 0.72
(95% C.I. 0.55 – 0.94) for BC and colon-rectum cancer, 0.76 (95% C.I. 0.48 – 1.14) for BC and
corpus uteri cancer (not significant).
Conclusion: This method proved to be useful in disentangling the effect of different subsequent
cancers on mortality. In our application it shows a worse long-term mortality for women with two
cancers than that with BC only. However, the increase in mortality was lower than expected under
the additivity assumption.
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The improvement of patients survival for the vast majority
of neoplasms led to a substantial increase in the probabil-
ity of further developing subsequent primary tumours.
However, the study of multiple primary tumours on a
population basis posed many additional problems. There
is, indeed, a problem of differential diagnosis, when it
comes to distinguish between local and distant metas-
tases, recurrences and the onset of a truly new lesion. Clas-
sifications may also vary leading to substantial differences
in rates. For example Surveillance Epidemiology and End
Results (SEER) rules [1] differ substantially from those
adopted by International Agency for Research on Cancer
(IARC) [2].
Furthermore, survival of patients with multiple tumours
has been neglected in population-based analyses, where
they are usually list-wise deleted, or analysed for the first
tumour occurrence only [3,4]. Only recently two studies
[5,6] reconsidered this exclusion policy. On the contrary,
in clinical series survival of patients with multiple
tumours is usually defined clinically and specific cause of
death is assessed accordingly. However, in population
studies and in series from cancer registries, clinical infor-
mation on patients follow-up is often unavailable and
assessment of cause of death is based only on death certif-
icates, often liable to gross misclassification. Heinävaara
et al. [7] proposed to estimate the differential amount due
to first or second tumour with a statistical parametric
model. Their application dealt with patients with two pri-
mary breast cancers, where the question of disentangling
the cancer-specific survival due to the first or the second
tumour is more difficult, also from a clinical point of
view. In the case of a subsequent primary cancer of a dif-
ferent origin the question is apparently simpler, although
not yet investigated on a population basis.
The following questions can be raised: whether the overall
survival of patients has decreased because of the interac-
tion between the two cancers, or if it has been left substan-
tially unchanged in comparison to those with one cancer
only, or even increased. For example, active surveillance
and care due to the first cancer can lead to earlier diagno-
sis of subsequent cancers and therefore to a longer sur-
vival (or a longer lead time). However, before studying the
possible effect of surveillance and other prognostic factors
(which was not the aim of this study), we should focus on
the correct measurement of survival, which is our research
objective.
To achieve this, we had to face many complex methodo-
logical challenges: first, we had to fix the zero reference
time (the time from when we started the follow-up); sec-
ond, a person can die only once thus the background
death rate is confounded in the follow up information
after the diagnosis of the second primary, therefore it is
crucial to use models able to suitably describe a situation
of competing risks; third, in order to make inferences, for
each model we had to define the correct expected survival
based on the appropriate comparison group.
We focused our attention on the following questions:
A. Does the survival probability of a patient with a second
primary tumour differ from those with only first type of
tumour?
B. Does the survival probability of a patient with a second
primary tumour differ from those with only second type
of tumour?
If a difference in survival is found in some of the previous
situations, a third more fundamental question arises.
C. Are the probabilities of surviving two subsequent pri-
mary tumours independent?
Studying survival probabilities in terms of the underlying
hazard of death, the question can be rephrased as follow:
Is the mortality rate after a second tumour simply the sum
of the two intensities (additivity hypothesis), or the way
the mortality rates act follows a different functional law?
This paper aims at answering these questions for women
with breast cancer and a subsequent primary tumour, pay-
ing particular attention to the conditional survival proba-
bility due to the time elapsed between the two
malignancies.
Methods
Statistical analysis
To correctly defining the probability of surviving condi-
tional to be alive up to the occurrence of a second tumour,
we started by writing questions A, B and C as hypothesis
in term of mortality hazard. We defined:
λA(t): mortality rate for the population with two tumours
at time t from the occurrence of the first tumour;
λB(t): mortality rate for the population with two tumours
at time t from the occurrence of the second tumour;
λC, α(t): mortality rate at time t from the occurrence of the
second tumour for the population with a second tumour
given that they already survived a time interval α.
We can break these down as
λA(t) = λ1|0(t) + λ1|2(t) + λ0Page 2 of 10
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where, for i = 1, 2, λi|0 is the specific mortality rate at time
t from the occurrence of tumour i for the population with
only that tumour, and λ0 is the general mortality.
We assumed that λ1|0, λ2|0 and λ0 were known, by previous
studies on mortality and survival in population with the
first type of tumour only, with the second type of tumour
only, and in the general population, respectively.
We observed that λ1|2(t) was the possible difference in
mortality rate in patients with a tumour of type 1 followed
by a tumour of type 2 with respect to that of patients with
a tumour of type 1 only, measured from the occurrence of
tumour 1; λ2|1(t) was the possible difference in mortality
rate in patients with a tumour of type 1 followed by a
tumour of type 2 with respect to that of patients with a
tumour of type 2 only, measured from the occurrence of
tumour 2.
Questions A, B, and C can be written as follows:
Occurrence probabilities conditioned to different events
(occurrence of a second cancer, death) in each time inter-
val can be estimated with the Aalen-Johansen [8] (AJ)
method in the framework of a Markov process, as
described later. Once we obtained these conditional prob-
abilities, we calculated the number of expected deaths by
sex, age, calendar period and follow-up time, under the
different hypotheses A, B and C. From a practical point of
view, we calculated the expected deaths in a similar way to
that used to calculate the denominator of relative survival
[9]. For example, in the case of a woman diagnosed with
breast cancer at 62 who developed a rectal cancer after two
years and survived for an additional period of five years,
we associated an expected probability of dying with a
breast cancer, occurred at the same age, for the two years
elapsed with that cancer only. Subsequently, we associ-
ated an expected probability of dying with breast and/or
with rectal cancer for the following years, taking into con-
sideration the ageing of the patient (i.e. using the annual
probability of dying according to the age of the patient,
from age 64 to age 69). The way the calculation of the
expected number of death (or the expected probability of
dying) for the conjoint period when both tumours are
present is performed depends on which one of the three
hypotheses we are testing. If we consider hypothesis A, we
do not add the probability of dying with a colon-rectum
cancer. If we test hypothesis B, we do not add the proba-
bility of dying associated to a breast cancer for the first
period. Finally, if we test hypothesis C (additive hypothe-
sis), we sum the two underlying mortality hazards during
the second period. Expected probabilities were derived
from analyses of the cohort of patients with only one inci-
dent cancer included in the cancer registry's data.
For the interested reader, we now explain in details how
we calculated expected probabilities. Since different states
are concerning, we resorted to the theory of Markov mod-
els [8]. In a Markov process individuals can belong to a
finite set of states and move to one state to some others
with a probability, possibly depending on time. The main
hypothesis is that the probability of moving from state i to
state j at time t depends on i, j and t only, and not on the
previous history of the individual.
We constructed a simple model with three states
1 first tumour
2 second tumour
3 death after a first (but not a second) tumour
where 2, and 3 are absorbing states and the possible
moves are: 1 → 2, 1 → 3.
Since our data showed right censoring, transition proba-
bilities Pij(s, t) from state i to state j, in the time interval (s,
t) were calculated using Aalen-Johansen (AJ) estimators
[8].
The procedure we adopted included age standardisation,
and precisely:
• For each age class k we calculated the AJ estimator Pijk(s,
t). We let Nk be the number of subjects in class k at time 0
and we set a weight , where N equals the sum of
the Nk's.
• We defined the standardised estimator as:
• It is reasonable to assume that weights are deterministic
(fixed) variables; under this assumption we have:
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estimators, it was possible to compare observed mortality
with mortality expected in the hypothesis of no interac-
tion between the two tumours; that is the mortality inten-
sities due if the two tumours were independent. As a
consequence, the number of expected deaths is the sum of
the deaths due to mortality for both tumours acting sepa-
rately. We calculated the number of expected deaths con-
sidering for each patient j the time of occurrence of the
first primary malignancy T1j, time of occurrence of the sec-
ond primary malignancy T2j, and, most important, the
time interval between the occurrence of the two tumours
αj = T2j - T1j. Each patient, after a time interval t2 since the
inception of the second tumour, has a probability p2j(t2)
of dying for the second tumour or general mortality equal
to that of the general population of patients with only that
type of tumour, according to her/his age, sex, calendar
period of diagnosis and follow-up time. In addition, that
patient has a probability p1j(t2 + αj) of dying at the (t2 +αj)- time interval for the first tumour or general mortality
again equal to that of the general population of patients
with that type of tumour only, according to her/his age,
sex, calendar period of diagnosis and follow-up time.
We set (t2) = p2j(t2)·(1 - p0j) where p0j is the general
mortality of the subject j according to her/his age, sex, cal-
endar period of diagnosis, taken from the life tables of the
general population. Thus, we can say that (t2) is the
specific mortality for the second tumour.
Therefore, within the cohort of patients with two malig-
nancies, at the t2 time interval since the second tumour, in
the hypothesis of no interaction between the mortality
forces of the two tumours, we expect the following
number of deaths:
where the probability of dying for the second tumour
(t2) is corrected by the probability of surviving from
the first tumour and general mortality 1 - p1j(t2 + αj).
Since the output of these calculations was the number of
expected deaths, we consequentially compared it with the
observed number in a ratio similar to the well known
Standardised Mortality Ratio:
We used the term SMRAJ because it was quite similar to the
standard term "SMR"in the sense that it was that ratio of
observed to expected deaths; the expected deaths were cal-
culated as a sum over age groups; and finally, it was simi-
lar to the indirect method of age standardisation since, as
standard, we applied the mortality rates of the cohort of
patients with only one tumour.
Patients
We selected all incident breast cancer cases recorded by
the Piedmont Cancer Registry in the resident women of
Turin from 1985 to 1998. This cohort of patients was fol-
lowed up for four years until the end of 2002, both for
what concerns life status or development of a subsequent
tumour (excluding skin carcinoma). Life status of women
who emigrated outside the resident population observed
by the Piedmont Cancer registry was ascertained with an
active follow-up at the municipality rosters of the new res-
idency. In this analysis we considered women with cancer
of corpus uteri or cancer of colon-rectum as second pri-
mary tumour, since we observed a consistent number of
cases (91 for colon-rectum and 62 for corpus uteri) for
making reasonable stable estimates. In addition, we ana-
lysed all types of second primary cancers (escept skin car-
cinomas) including corpus uteri and colon-rectum. For
age standardisation, we introduced age at diagnosis in five
broad classes: 0 – 44, 45 – 54, 55 – 64, 65 – 74, 75+. Age
standardisation for the unconditional survival estimates
were calculated using those standards proposed by
Corazziari et colleagues [10] for comparisons in interna-
tional studies.
We calculated λ1|0 from our cohort of 8234 women with
breast cancer only. Mortality for the second type of
tumour (λ2|0) was calculated from 1443 women with cor-
pus uteri cancer only, and from 4050 women with colon-
rectum cancer only. In the case of mortality for all cancers
λ2|0 was calculated in two ways: including breast cancers
(28737 women), and excluding breast cancers (20082
women). We also used overall mortality including breast
cancer, as a reference for comparing available published
statistics that usually do not make exclusions for specific
type of cancers. Life tables for the general mortality were
from the Statistics Office of Turin for the period 1985–
2002.
Results
We identified 9233 women with breast cancer in Turin
from 1985 to 1998, 563 cases were excluded as they were
identified from Death Certificate Only (DCO) or synchro-
nous primary tumours (same day of diagnosis for the two
tumours) or they were patients with more than two
tumours, leaving 8670 cases for analysis. From this
cohort, 436 second (metachronous) primary tumours
developed during the prolonged follow-up period (1985–
2002). The most frequent types of subsequent cancers
were colon-rectum (91 patients) and corpus of uteri (62
pˆ j2
pˆ j2
{ ( ) [ ( )] ( )};p t p t p tj j j j j
j
1 2 1 2 2 21+ + − + ⋅∑ a a
pˆ j2
SMR tAJ = Number of observed deaths at time Number of expected deaths at time t .Page 4 of 10
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two tumours was five years, but with an highly positive
skewed distribution. The completeness of clinical docu-
mentation was rather high, considering that registries
work on a population basis, with a 94.5% of microscopic
confirmation for first tumours that reached 99.3% for sec-
ond tumours.
At the end of the study period (2002), we observed 285
(65.4%) deaths among women with a second tumour,
distributed as in table 1, and 3931 (47.7%) among
women with breast cancer only.
Using a traditional approach, starting from the diagnosis
of the first tumour (breast cancer), we had, at 1, 5 and 10
years respectively, an age standardised survival of 96.1%,
74.3% and 43.6% for the 436 women with two cancers,
while it was 94.0%, 72.9% and 56.9% for women with
breast cancer only (Table 2). On the contrary, survival of
women with one tumour only (all site including breast
cancer) was worse: 69.5%, 47.5%, and 37.1% after 1, 5
and 10 years of follow-up. Also survival of women with
colon-rectum or corpus uteri cancer only was worse than
that of women with a subsequent cancer, when starting
follow-up since diagnosis of breast cancer. Their higher
survival is due to the fact that patients with multiple can-
cers had survived an extra amount of time (a median of
five years) before developing the subsequent cancer in
comparison with patients with a single cancer only. A less
biased and more appropriate comparison can be obtained
moving the zero time point to the date of diagnosis of the
second tumour. In this case, the survival of patients with
breast cancer and a subsequent tumour was rapidly
decreasing since the date of diagnosis of the second
tumour, and comparable to that of patients with only one
tumour excluding breast cancer. Also survival of patients
with breast and colon-rectum cancer was rapidly decreas-
ing after the first year, when it was still comparable, and
lower (20.8% versus 32.9%), although not statistically
significantly, than that of patients with colon-rectum can-
cer only. Survival of patients with breast and corpus can-
cers was generally quite high, with 70.6% of women still
alive after 10 years since the breast cancer and 44.2% alive
after 10 years since the corpus uteri cancer diagnosis.
However, patients with corpus cancer only showed a
higher survival at 10 years (56.6%).
In table 3 we compared the number of observed deaths
with the expected deaths under the three hypotheses A, B
and C. We calculated the number of expected deaths tak-
ing into account the probabilities of surviving the first
tumour, developing a second tumour and subsequently
dying. We presented the expected deaths broken down
according to the three different probabilities. The
expected numbers of deaths under the first hypothesis (A)
were definitively below the observed numbers since they
did not take into account the probability of dying because
of the second tumour. On the other hand, the expected
number of deaths from the unconditional probabilities of
dying for the second tumours (hypothesis B) were overes-
timated (291.8) in the case of all cancers and slightly
underestimated in the case of colon-rectum (53.45) and
corpus uteri cancers (19.16). The expected numbers of
deaths according to the probabilities of dying because of
the second tumour, given that the patients survived the
first, were 248.30 for all cancers, 44.76 for colon-rectum
cancer and 15.81 for corpus uteri. Summing up the latter
figures with the expected numbers for hypothesis A, we
obtained the expected number of deaths according to the
additivity hypothesis C. Considering the ratio between
Table 1: Distribution of subsequent primary malignancies and 
deaths among a cohort of women with breast cancer in Turin 
from 1985 to 1998 (follow-up 2002)
Second cancer Number of cases Observed deaths
Head & Neck 16 11
Stomach 31 28
Colon-Rectum 91 57
Liver & Gallbladder 20 19
Pancreas 25 23
Lung & Pleura 34 32
Melanoma of skin 15 2
Cervix Uteri 10 5
Corpus Uteri 62 23
Ovary 29 20
Bladder 14 7
Kidney 12 5
Brain & CNS 5 5
Thyroid Gland 14 5
NHL 24 16
Leukaemia 13 9
Others 21 18
Total 436 285Page 5 of 10
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hypothesis is not confirmed for all cancers (SMRAJ 0.75
95% CL 0.66–0.84), or for colon-rectal cancer (SMRAJ
0.72 95% CL 0.55–0.94) while in the case of corpus uteri
cancer we cannot reject the hypothesis that mortality rates
are additive. The differences between the three models
and observed deaths is visualised in Figure 1 where cumu-
lative numbers of deaths are displayed over years of fol-
low-up. It can be seen that in all graphs hypothesis C
(additivity) tends to overestimate the actual observed
trend, hypothesis A strongly underestimates it, while
hypothesis B is the closest to observed data, especially
during the first time (years) of follow-up.
Discussion
The dramatic improvement of cancer survival during the
last decades in Western countries brought with it a new
health threat: the development of second primary cancers
in survivors. An editorial in CEBP of David Alberts clearly
stated that 'Second cancers are killing us! ' [11]. However,
in spite of the fact that several studies on the multiple pri-
mary cancer risk were undertaken [12], the rate at which
first and second, or higher-order cancers are killing us
remains neglected. In clinical studies, when reliable infor-
mation are available it is often possible to understand if
the pathological conditions linked to a specific cancer
affected the patient survival and to which extent. How-
Table 2: Age standardised observed survival (%) according to various traditional unconditional approaches – at 1, 5 and 10 years of 
follow-up in women with two cancers (since the diagnosis of the first or second tumour) compared with women with one cancer only.
PATIENTS GROUPS number of patients 1 year since diagnosis 5 years since diagnosis 10 years since diagnosis
One primary cancer only (all tumours excluding 
breast cancer) (95% C.L.)
20082 58.9
(58.3–59.2)
36.5
(34.9–37.1)
28.5
(27.7–29.3)
One primary cancer only (all tumours including 
breast cancer) (95% C.L.)
28316 69.5
(68.9–71.1)
47.5
(46.9–48.1)
37.1
(36.3–37.9)
Breast cancer only
(95% C.L.)
8234 94.0
(93.4–94.6)
72.9
(70.0–73.9)
56.9
(55.5–58.3)
Colon-Rectum cancer only
(95% C.L.)
4050 68.4
(66.8–70.0)
42.9
(41.1–44.7)
32.9
(30.7–35.1)
Corpus Uteri cancer only
(95% C.L.)
1443 87.8
(86.0–89.6)
69.0
(51.1–82.5)
56.6
(15.9–76.7)
Breast cancer with second primary cancer, f.u. 
starting from breast cancer diagnosis
(95% C.L.)
436 96.1
(93.8–97.5)
74.3
(69.5–78.5)
43.6
(36.6–50.9)
Breast cancer with second primary cancer, f.u. 
starting from second primary cancer diagnosis
(95% C.L.)
436 61.7
(57.0–66.1)
37.8
(29.5–46.8)
24.6
(10.8–46.8)
Breast cancer with subsequent Colon-Rectum 
cancer with f.u. starting from breast cancer 
diagnosis
(95% C.L.)
91 97.8
(92.3–99.4)
72.4
(61.7–81.1)
43.7
(28.7–59.9)
Breast cancer with subsequent Colon-Rectum 
cancer with f.u. starting from Colon- Rectum 
cancer diagnosis
(95% C.L.)
91 70.3
(60.3–78.7)
38.9
(21.9–58.9)
20.8
(2.9–69.2)
Breast cancer with subsequent Corpus Uteri 
cancer with f.u. starting from breast cancer 
diagnosis
(95% C.L.)
62 100.0
-
91.9
(82.2–96.6)
70.6
(53.7–83.2)
Breast with subsequent Corpus Uteri Cancer with 
f.u. starting from Corpus Uteri cancer diagnosis
(95% C.L.)
62 88.7
(78.5–94.4)
68.9
(51.1–82.5)
44.2
(15.9–76.7)Page 6 of 10
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due to the lack of clinical information or cause of death.
Even when cancer-specific causes of death are available,
they are subject to various degrees of misclassification,
hindering the possibility of a reliable estimate of cancer
specific survival. In the main population based statistics
on cancer survival worldwide available (Eurocare [3] and
SEER [4]) subsequent cancers were excluded: only the first
occurring cancer was analysed, or all the subjects with
multiple cancers were deleted from analysis. Although,
this strategy has recently undergone through a rethinking
[5,6], it was supposed to allow for more comparable
results across registries with different back up informa-
tion, and therefore with a different possibility in identify-
ing those cancers that occurred in prevalent cases.
However, we believe that the problem deserves more
attention also from its implication in the management
and care of such patients. Indeed, a wider availability of
effective cancer treatments has prolonged patient survival,
so increasing the possibility of developing another cancer.
Studying the occurrence of multiple tumours and their
association, it emerged as the higher susceptibility to sub-
sequent malignancies can possibly be due to unfavorable
genetic pattern or common exogenous risk factors
[13,14]. Multiple cancer survival is also a stimulating
topic of study, but received less attention. Recently, an
analysis of the SEER data on multiple tumours following
breast cancer [15] showed that survival of women 20–29
years old at time of breast cancer diagnosis had a worse
10-year survival, compared with women with breast can-
cer only, while there were no differences in the 5-year sur-
vival. However, in that analysis the time elapsed until the
second cancer occurrence was not taken into account.
Before investigating the reasons influencing survival for
patients with multiple tumours, we, indeed, believe that it
is essential to have a correct measurement of survival that
takes into account the effect of conditional probabilities
of surviving given the different timing of primary cancers
occurrences. We proposed a method that assigns the cor-
rect number of expected events according to the different
components of mortality due to each type of cancer. The
proposed method is useful only in correctly stating the
prediction of mortality probabilities while cannot explain
the causes of the different mortality probabilities.
The expected number of deaths was calculated taking into
account the exact time spent at risk of dying for one or
another cancer by age classes and calendar period, using
conditional probabilities estimated by the AJ estimator
Table 3: Observed and expected number of deaths, according to various hypotheses, in women with breast cancer and with a 
subsequent primary tumour after 10 years from the reference time. 
Conditional probability Subsequent primary tumour
All cancers Colon-Rectum Corpus Uteri
observed number of deaths 285 57 23
expected number of deaths from the first (breast) cancer
- Hypothesis A
p1(t + αj) 129.22 34.01 14.45
SMRAJ – Hypothesis A
(95% CL)
2.21
(1.94 – 2.45)
1.68
(1.27 – 2.17)
1.59
(1.01 – 2.39)
expected number of deaths from the second cancer
- Hypothesis B
p2(t) 291.8 53.45 19.16
SMRAJ – Hypothesis B
(95% CL)
0.98
(0.87 – 1.10)
1.07
(0.81 – 1.38)
1.20
(0.76 – 1.80)
conditional expected number of deaths from the second cancer
(t)·(1 - p1(t + αj)) 248.30 44.76 15.81
expected deaths based on conditional probabilities
- Hypothesis C (additive)
p1(t + αj)+
+ (t)·(1 - p1(t + αj))
377.5 78.77 30.26
SMRAJ – Hypothesis C
(95% CL)
0.75
(0.66 – 0.84)
0.72
(0.55 – 0.94)
0.76
(0.48 – 1.14)
Expected numbers were calculated stratifying by age classes and calendar period (hypotheses A and B) and allowing for general mortality in women 
(hypothesis C). See Methods for definition of probabilities pi and of SMRAJ.
pˆ2
pˆ2Page 7 of 10
(page number not for citation purposes)
Emerging Themes in Epidemiology 2009, 6:2 http://www.ete-online.com/content/6/1/2
Page 8 of 10
(page number not for citation purposes)
Cumulative number of deaths following different hypotheses for women with a second cancer after breast cancerFigure 1
Cumulative number of deaths following different hypotheses for women with a second cancer after breast can-
cer: (i) all tumours (ii) colorectal cancer (iii) corpus uteri cancer.
Emerging Themes in Epidemiology 2009, 6:2 http://www.ete-online.com/content/6/1/2from a simple one-way Markov process with two absorb-
ing states. Such approach was recommended since it
allowed a better control of probabilities of events arising
from different states. In the model referring to hypothesis
A, we calculated the expected number of deaths due to the
first occurring cancer starting since its time of occurrence.
This model is similar to model 2 proposed by Heinävaara
and colleagues [7] in the absence of cancer specific cause
of death. We wrote the model's parameters in terms of risk
excess (hazard rate), rather than estimating the specific
mortality rates. While survival of patients with a second
primary tumour was comparable or higher with that of
those patients with breast cancer only during the first
years, it was rapidly declining at a higher rate than the ref-
erence group after five years of follow-up. This effect was
explained by the fact those patients had survived an extra
amount of time (a median of five years) before develop-
ing the subsequent cancer. Indeed, results from hypothe-
sis A showed an increased cumulative mortality only at
ten years for women with two cancers when compared to
those with breast cancer only, as found in the study of
Raymond and Hogue [15].
The second model (hypothesis B) was built with the same
structure as model A, calculating the expected number of
deaths due to the second occurring cancer starting since its
time of occurrence. However, the change in the baseline
population and the shift in the time zero reference made
the hazard rates not comparable. Indeed, for a proper
comparison with those patients with the second type of
cancer only, we set the starting time at the diagnosis of the
second cancer. In this case, the survival was comparable at
1 and 5 years of follow-up, than that of patients with one
type of cancer only, while it was slightly shorter at 10
years. In summary, results from hypothesis B showed no
extra mortality compared to patients with only one cancer
of the same type, and observed and expected number of
deaths closely get on during the years of observation.
We then addressed the question of evaluating the eventual
extra mortality due to the combination of effects of the
two primary neoplasms, checking the hypothesis if the
mortality of women with two cancers was due to the sum
of the baseline mortality rates of breast and other cancers
(additivity hypothesis C). It clearly emerged how
observed cumulative mortality was lower than expected
under the additivity assumption, with a statistically signif-
icant difference in the case of all cancers and colon-rectum
after 10 years of follow-up. The agreement of a specific
model to observed data was therefore useful for having
further hints of the underlying mechanisms. In our study,
the less than expected results can be explained by the fact
that the second cancer can have a less advanced stage and
therefore a better prognosis, since a subsequent cancer is
usually diagnosed because of a deeper clinical surveillance
due to the first cancer. It is clear that women with breast
cancer and a subsequent cancer survive less than women
with breast cancer only, but their survival is not always
decreased simply as it would be if the forces of mortality
work together in an additive way.
The study has some possible limitations. First of all, the
method of correction is based on observed rates (mortal-
ity rates measured in the cohort of patients with only one
tumour) that, when based on small numbers, can be
unstable. Then, this method, being inherently non-para-
metric, does not give information on the underlying inci-
dence/mortality competing laws. In calculating expected
number of deaths a possible bias could have been intro-
duced, depending on the numbers of patients who emi-
grated outside the Cancer Registry's area. In this case,
information on life status were still available and col-
lected, but we did not know if the patient had developed
a subsequent cancer when resident in another area. Dur-
ing the study period, we observed about 8% of women
who emigrated among those classified with breast cancer
only. Their median time of emigration was 6.5 years since
the breast cancer diagnosis. As a consequence, considering
that the median time for developing a second primary
cancer was about 5 years, the detection bias should be very
limited. Finally, the method was presently tested only on
a limited set of data: patients with breast cancer as a first
primary tumour. As few studies are still available on this
topic, more research is needed, with larger samples and
including clinical data (e.g. stage at presentation, hor-
mone receptor status), therapies (e.g. tamoxifen), infor-
mation on follow-up circumstances, and modality of
diagnosis. In conclusion, we showed that the presented
approach for calculating conditional probabilities was
correct when dealing with situations, as with multiple
tumours, where competing causes of death can bias the
results of survival probabilities. We also pointed out how
shifted reference times can be considered in correctly
comparing survival. In addition, departure from the
expected additive model can give hints towards which
direction to further investigate.
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